Skip to main content
N4 PHARMA PLC logo

N4 PHARMA PLC — Investor Relations & Filings

Ticker · N4P ISIN · GB00BYW8QM32 LEI · 213800I841D2RKMFK955 IL Professional, scientific and technical activities
Open in API
Filings indexed 840 across all filing types
Latest filing 2022-10-10 Regulatory Filings
Country GB United Kingdom
Listing IL N4P

About N4 PHARMA PLC

https://n4pharma.com/

N4 Pharma PLC is a specialist pharmaceutical company focused on the development of Nuvec®, its proprietary silica nanoparticle delivery system. This platform technology is designed to enhance the cellular delivery and potency of nucleic acid-based treatments, such as vaccines and cancer therapies. The company's primary focus is on applying Nuvec® to enable advanced therapies for oncology and infectious diseases. N4 Pharma's business model involves developing and out-licensing its technology to pharmaceutical and biotechnology partners to improve the performance of new and existing drugs.

Recent filings

Filing Released Lang Actions
Second Price Monitoring Extn
Regulatory Filings Classification · 1% confidence The document is very short (1933 characters) and contains the header 'RNS Number : 3418C'. It announces a 'Second Price Monitoring Extension' related to trading activity, which is a specific operational announcement. The text explicitly mentions 'RNS, the news service of the London Stock Exchange' and is clearly a regulatory notification rather than a comprehensive financial report (like 10-K or IR). Since it is a specific regulatory announcement that doesn't fit the other specialized codes (like DIRS, DIV, or DLST), the most appropriate classification is the general regulatory filing category, RNS.
2022-10-10 English
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document is very short (1916 characters) and contains the header 'RNS Number : 3404C'. It announces a 'Price Monitoring Extension' related to trading on the London Stock Exchange. The text explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' This indicates it is a general regulatory announcement or news service update that does not fit into the specific financial report categories (like 10-K, ER, IR). Therefore, the most appropriate classification is the general Regulatory Filings category (RNS).
2022-10-10 English
SFX-01 licensing deal for up to $160.5m
M&A Activity Classification · 1% confidence The document begins with 'RNS Number' and is dated '10 October 2022'. It details a significant corporate event: a licensing deal for the asset SFX-01 between Evgen Pharma plc and Stalicla SA, including financial terms and strategic rationale. The text explicitly states, 'The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 (as implemented into English law) ("MAR"). With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.' Furthermore, the document concludes with standard RNS closing information, including contact details for RNS and the London Stock Exchange. This structure strongly indicates a general regulatory news service announcement, which falls under the 'Regulatory Filings' (RNS) category, as it is not a specific financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A). It is a material corporate event disclosure via the official channel.
2022-10-10 English
Double siRNA Testing Update
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number : 6141B' and is dated '04 October 2022'. It contains an announcement titled 'Double siRNA Testing Update' regarding successful in vitro testing of their product, Nuvec®. It explicitly mentions that the information is deemed 'inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014' and is provided by 'RNS, the news service of the London Stock Exchange.' This structure—a brief update on operational/scientific progress disseminated via the RNS system—is characteristic of a general regulatory announcement that doesn't fit the more specific categories like ER (Earnings Release) or 10-K (Annual Report). Since it is a regulatory announcement disseminated through the official channel (RNS) and doesn't fit other specific types, the most appropriate classification is Regulatory Filings (RNS). The document length (4091 chars) is short, but it is the primary announcement itself, not just an announcement *about* another report, so RPA is less suitable than RNS for this type of operational update.
2022-10-04 English
Regulatory approval for healthy volunteer study
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number' and is dated September 29, 2022. It contains an announcement from Evgen Pharma plc regarding regulatory approval for a new study concerning their lead asset SFX-01. The text structure, the presence of the RNS header, and the nature of the announcement (a specific, timely corporate update that is not a full financial report, management change, or dividend notice) strongly suggest it is a general regulatory announcement distributed via the London Stock Exchange's news service. This fits the definition of a Regulatory Filing (RNS), which serves as a general announcement category for such disclosures.
2022-09-29 English
Interim Results
Earnings Release Classification · 1% confidence The document explicitly states it announces the "unaudited interim results for the six months ended 30 June 2022." This content, which includes financial highlights (operating loss, cash position) and a detailed operational update covering R&D progress (oncology, siRNA, oral studies), is characteristic of a comprehensive financial report covering a period shorter than a full year. This aligns perfectly with the definition of an Interim / Quarterly Report (IR). Although it is distributed via RNS (Regulatory Information Service), the core content is the financial report itself, not just an announcement of its publication (RPA/RNS). H1 2022
2022-09-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.